Skip to main content
Erschienen in: Drug Safety 6/2007

01.06.2007 | Original Research Article

Surveillance of Prescription Drug-Related Mortality Using Death Certificate Data

verfasst von: Dr Diane K. Wysowski

Erschienen in: Drug Safety | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Background: The prescription drugs or drug classes that are most frequently associated with death in the US might be identifiable from death certificate data.
Objective: To identify the drugs/drug classes associated with the greatest numbers of deaths in the US that might be considered as possible targets for prevention.
Study design: US vital statistics data were accessed in order to identify International Classification of Diseases (10th Revision) [ICD-10] codes indicating that prescription drugs had caused or contributed to death and diseases with significant drug-related mortality.
Main outcome measure: ICD-10 codes for primarily prescription drugs that were listed as the underlying cause or as ‘total mentions’ on death certificates and were implicated in ≥1000 deaths in any one year were selected. The annual number of deaths by ICD-10 code was obtained from the Division of Vital Statistics, National Center for Health Statistics. Codes for diseases with significant drug-related aetiologies and involvement in ≥1000 deaths in any one year were also identified and analysed separately.
Results: For the selected ICD-10 codes, a total of 25 031 deaths were listed as having a prescription drug as the underlying cause in 2003, compared with 16 135 in 1999, a 55% increase. Total mentions of these codes increased from 46 523 in 1999 to 72 080 in 2003, also a 55% increase. Most codes involved ‘poisonings’ (overdose or the wrong substance given or taken in error that is accidental, intentional or with undetermined intent). Drugs associated with poisoning deaths had central nervous system effects. Among the codes associated with specified drug classes, poisonings and accidental poisonings involving narcotics, hallucinogens, psychoactive substances and opioids (other than opium and heroin) were associated with the largest numbers of deaths. Drug-related codes associated with the largest percentage increases in deaths between 1999 and 2003 included poisoning due to methadone (275%); poisoning by other and unspecified antidepressants (primarily selective serotonin reuptake inhibitors) [130%]; and poisoning by psychostimulants with potential for abuse (amfetamines and drugs for attention deficit hyperactivity disorder) [117%]. Anticoagulants were associated with the largest numbers of deaths with codes involving “adverse effects in therapeutic use”. Among diseases with significant drug-related aetiologies, Clostridium difficile enterocolitis (associated primarily with antibacterials) had the largest percentage increase in total mentions, with a 203% rise between 1999 and 2003.
Conclusions: Deaths due to overdoses are the most prominent cause of drug-related mortality in death certificate data. Certain drugs and drug classes, especially the opioids (e.g. narcotics, methadone), psychoactive drugs (e.g. antidepressants, amfetamines), anticoagulants and antibacterials (which cause or contribute to C. difficile enterocolitis) are associated with large and increasing numbers of deaths and preventive strategies should be considered.
Literatur
1.
Zurück zum Zitat Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363–9PubMedCrossRef Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med 2005; 165: 1363–9PubMedCrossRef
2.
Zurück zum Zitat International Statistical Classification of Diseases and Related Health Problems, Tenth revision, (ICD-10). Geneva: World Health Organization, 1992: volume 1 International Statistical Classification of Diseases and Related Health Problems, Tenth revision, (ICD-10). Geneva: World Health Organization, 1992: volume 1
4.
Zurück zum Zitat Pepin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1999 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466–72PubMedCrossRef Pepin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1999 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466–72PubMedCrossRef
5.
Zurück zum Zitat Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442–9PubMedCrossRef Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442–9PubMedCrossRef
6.
Zurück zum Zitat Bartlett JG, Perl TM. The new Clostridium difficile — what does it mean? N Engl J Med 2005; 353: 2503–5PubMedCrossRef Bartlett JG, Perl TM. The new Clostridium difficile — what does it mean? N Engl J Med 2005; 353: 2503–5PubMedCrossRef
7.
Zurück zum Zitat Kaufman DW, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anemia: monographs in epidemiology and biostatistics, volume 18. New York: Oxford University Press, 1991 Kaufman DW, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anemia: monographs in epidemiology and biostatistics, volume 18. New York: Oxford University Press, 1991
8.
Zurück zum Zitat Ibanez L, Vidal X, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165: 869–74PubMedCrossRef Ibanez L, Vidal X, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165: 869–74PubMedCrossRef
9.
Zurück zum Zitat Shapiro S, Issaragrisil S, Kaufman DW, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 1999; 60: 573–7PubMed Shapiro S, Issaragrisil S, Kaufman DW, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 1999; 60: 573–7PubMed
10.
Zurück zum Zitat Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–63PubMed Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–63PubMed
11.
Zurück zum Zitat Lassen A, Hallas J, de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 2006; 101: 945–53PubMedCrossRef Lassen A, Hallas J, de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 2006; 101: 945–53PubMedCrossRef
12.
Zurück zum Zitat Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5PubMedCrossRef Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5PubMedCrossRef
13.
Zurück zum Zitat Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–90PubMedCrossRef Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–90PubMedCrossRef
14.
Zurück zum Zitat Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg 2001; 95: 1053–6PubMedCrossRef Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg 2001; 95: 1053–6PubMedCrossRef
15.
Zurück zum Zitat Wysowski DK, Pollock ML. Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review. Anesthesiology 2006; 105: 1047–51PubMedCrossRef Wysowski DK, Pollock ML. Reports of death with use of propofol (Diprivan) for nonprocedural (long-term) sedation and literature review. Anesthesiology 2006; 105: 1047–51PubMedCrossRef
16.
Zurück zum Zitat Wysowski DK, Nourjah P. Analyzing prescription drugs as causes of death on death certificates. Public Health Rep 2004; 119: 520PubMedCrossRef Wysowski DK, Nourjah P. Analyzing prescription drugs as causes of death on death certificates. Public Health Rep 2004; 119: 520PubMedCrossRef
17.
Zurück zum Zitat Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720–41PubMed Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720–41PubMed
18.
Zurück zum Zitat Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377–85PubMedCrossRef Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377–85PubMedCrossRef
19.
Zurück zum Zitat Sinert R, Kohl L, Rainone T, et al. Exercise-induced rhabdomyolysis. Ann Emerg Med 1994; 23: 1301–6PubMedCrossRef Sinert R, Kohl L, Rainone T, et al. Exercise-induced rhabdomyolysis. Ann Emerg Med 1994; 23: 1301–6PubMedCrossRef
20.
Zurück zum Zitat Wysowski DK, Governale LA, Swann J. Trends in outpatient prescription drug use and related costs in the US. Pharmacoeconomics 2006; 24: 233–6PubMedCrossRef Wysowski DK, Governale LA, Swann J. Trends in outpatient prescription drug use and related costs in the US. Pharmacoeconomics 2006; 24: 233–6PubMedCrossRef
21.
Zurück zum Zitat Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 618–27PubMedCrossRef Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 618–27PubMedCrossRef
22.
Zurück zum Zitat Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. JAMA 2005; 293: 297–8PubMedCrossRef Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. JAMA 2005; 293: 297–8PubMedCrossRef
23.
Zurück zum Zitat Dart RC, Woody GE, Kleber HD. Prescribing methadone as an analgesic. Ann Intern Med 2005; 143: 620PubMed Dart RC, Woody GE, Kleber HD. Prescribing methadone as an analgesic. Ann Intern Med 2005; 143: 620PubMed
24.
Zurück zum Zitat Mueller MR, Shah NG, Landen MG. Unintentional prescription drug overdose deaths in New Mexico, 1994–2003. Am J Prev Med 2006; 30: 423–9PubMedCrossRef Mueller MR, Shah NG, Landen MG. Unintentional prescription drug overdose deaths in New Mexico, 1994–2003. Am J Prev Med 2006; 30: 423–9PubMedCrossRef
25.
Zurück zum Zitat Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2003; 27: 57–67PubMed Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2003; 27: 57–67PubMed
27.
Zurück zum Zitat Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 2004; 25: 178–81PubMedCrossRef Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 2004; 25: 178–81PubMedCrossRef
28.
Zurück zum Zitat Barrueto F Jr, Howland MA, Hoffman RS. The fentanyl tea bag. Vet Hum Toxicol 2004; 46: 30–1PubMed Barrueto F Jr, Howland MA, Hoffman RS. The fentanyl tea bag. Vet Hum Toxicol 2004; 46: 30–1PubMed
29.
Zurück zum Zitat Meadows M. Proper use of fentanyl pain patches. FDA Consumer magazine March–April, 2006 Meadows M. Proper use of fentanyl pain patches. FDA Consumer magazine March–April, 2006
30.
Zurück zum Zitat Wysowski DK. Increase in deaths related to enterocolitis due to Clostridium difficle in the United States, 1999–2002. Public Health Rep 2006; 121: 361–2PubMed Wysowski DK. Increase in deaths related to enterocolitis due to Clostridium difficle in the United States, 1999–2002. Public Health Rep 2006; 121: 361–2PubMed
Metadaten
Titel
Surveillance of Prescription Drug-Related Mortality Using Death Certificate Data
verfasst von
Dr Diane K. Wysowski
Publikationsdatum
01.06.2007
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 6/2007
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730060-00007

Weitere Artikel der Ausgabe 6/2007

Drug Safety 6/2007 Zur Ausgabe